Transforming the future of regenerative medicine

The future of healthcare is promising, with growth and innovation led by advancements in regenerative medicine. Companies like Regenity Biosciences are pioneering advancements in regenerative science and transforming bioabsorbable materials into life-changing solutions.

An explosion of growth in regenerative medicine

The regenerative medicine market is rapidly expanding, driven by the rising prevalence of chronic conditions, demand for personalized therapies, and an aging population. With 1 in 6 U.S. adults over 65, there’s a growing need for innovative treatments that go beyond symptom management to enable true healing.

This need for advanced solutions has been met with stem cell therapy and tissue engineering breakthroughs like Regenity's FDA-cleared RejuvaKnee™, a collagen-based meniscal implant that facilitates the regeneration of native meniscal tissue instead of cutting or replacing it. This marks a shift from the standard of care with the potential to improve patients’ quality of life.

Gaining a competitive edge with a regenerative medicine CDMO

Medtech companies have a unique opportunity to enter the high-growth regenerative medicine market with support from contract development and manufacturing organizations (CDMOs) like Regenity, offering expertise, efficiency, and scalability in key areas:

1. Manufacturing expertise

Regenerative medicine products often require complex, specialized manufacturing processes. CDMOs ensure the highest quality and regulatory compliance through advanced capabilities in material sourcing, tissue engineering and proprietary biomaterial processes. Regenity’s end-to-end approach delivers unmatched quality, consistency, and efficiency for end products made from collagen, synthetic polymers, and other biomaterials.

2. Speed to market

With rapid innovation, CDMOs help companies reduce development timelines, save costs, and accelerate time-to-market. Regenity’s customized product development process can leverage its library of design assets to deliver a program from concept to commercialization in 15 months. Furthermore, its portfolio of private-brand “off-the-shelf” products can be ready to deploy in as little as 12-16 weeks, enabling medtech companies to capitalize on market demand swiftly.

3. Regulatory support

CDMOs provide critical support navigating complex regulatory landscapes, ensuring compliance with local and global standards. With 27+ years of experience, Regenity has 60 510(k) clearances, 24 CE marks, 2 China certificates, and approvals in 85+ countries on behalf of its customer base. This experience matters when it comes to supporting customers’ regulatory submissions, claims development, and clinical study design for regenerative devices.

4. Scalability and flexibility

Scaling production for commercial success requires flexibility, quality and consistency. CDMOs can offer seamless transitions from clinical trials to full-scale manufacturing. Regenity’s state-of-the-art facilities—spanning over 70,000 square feet in the U.S. and EU— provide immediate scalability in ISO Class 7 environments with established regulatory Certifications.

Looking ahead

Regenerative medicine is transforming healthcare, empowering medtech companies to innovate, stay competitive, and ultimately serve more patients. With CDMOs like Regenity providing expertise and scalability, companies can efficiently bring groundbreaking tissue engineering solutions to market, shaping the future of healthcare.